logo
  

Merck Launches NEXPLANON 68 Mg In U.S.

Merck & Co. (MRK) said Wednesday that NEXPLANON 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.
NEXPLANON is approved by the FDA for the prevention of pregnancy in women for up to three years.

NEXPLANON must be removed by the end of the third year and may be replaced by a new NEXPLANON, if continued contraceptive protection is desired.

About the size of a matchstick, NEXPLANON is made of a soft, flexible, medical polymer and is inserted just under the skin of a woman's upper arm in a minor surgical in-office procedure.

NEXPLANON is effective, when inserted correctly, with less than 1 pregnancy per 100 women who used NEXPLANON for 1 year. NEXPLANON may be less effective in women who are very overweight and in women who are taking medications that induce liver enzymes. NEXPLANON is a progestin-only contraceptive that does not contain estrogen. NEXPLANON does not depend on daily, weekly, monthly, or quarterly administration. Etonogestrel, the progestin in NEXPLANON, prevents pregnancy in three ways: inhibiting ovulation, thickening of the cervical mucus, and alterations in the endometrium.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bobo's recalled one lot of Bobo's 4-pack Almond Butter Protein Bars for potentially containing undeclared peanuts, the U.S. Food and Drug Administration or FDA said in a statement. The recall was initiated after it was discovered that product containing peanuts was distributed in packaging that did not reveal the presence of peanuts on the ingredient deck. Birmingham, Michigan-based RFA Brands LLC, d/b/a myCharge is recalling about 67,000 units of myCharge powerbanks citing fire and burn risks, the U.S. Consumer Product Safety Commission said. The recall was initiated after myCharge received 30 reports of the powerbanks overheating, resulting in seven injuries as well as property damage to household flooring, walls and furniture. Comcast Corp. (CMCSA, CMCSK) on Thursday reported that profit for the third quarter doubled from last year, driven by 19 percent revenue growth amid significant growth across each of its businesses. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend.
Follow RTT